News

Zacks.com on MSN2d
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?
Yahoo Finance3d
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
Two prominent companies with a strong foothold in this space are Hologic HOLX and Myriad Genetics MYGN. Hologic’s molecular diagnostics offerings specialize in women’s health and acute ...
Leerink Partners Sticks to Its Hold Rating for Myriad Genetics (MYGN)
In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...
ETF Daily News5d
The Goldman Sachs Group Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price
Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price cut by The Goldman Sachs Group from $18.00 to $14.00 in a research report report published on Thursday morning,Benzinga reports.
The Manila Times3d
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that ...
Nasdaq3d
Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations ...
Yahoo Finance3d
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...